Allegro DVT Fosters Adoption of MPEG-5 LCEVC Video Codec, Releases a Full Range of LCEVC Products
31.8.2023 16:00:00 EEST | Business Wire | Press release
Allegro DVT, a leading provider of Video codec compliance streams and silicon video IP solutions has launched a complete range of MPEG-5 LCEVC products comprising LCEVC compliance streams and LCEVC hardware decoder and encoder video IPs (D301 and E301).
Allegro DVT’s LCEVC Compliance Streams are crucial to confirm that decoder implementations adhere to the LCEVC standard. They are used by all companies developing SoCs or devices with LCEVC decoding capabilities.
Furthermore, Allegro DVT is also releasing its E301 LCEVC Encoding HW IP which complements its D301 LCEVC Decoding HW IP that was previously announced at NAB in April 2023. This full range of LCEVC HW IPs is suitable for integration into SoCs/ASICs requiring HW based support for LCEVC encoding and decoding functions.
The E301 is the industry’s first LCEVC encoding IP solution and was developed in close collaboration with V-Nova, the inventor of the LCEVC technology. It is optimized for power and silicon area, allows system-on-chip (SoC) and ASIC designers to easily integrate LCEVC encoding into their products. It supports picture resolution up to 8K, pixel widths from 8 to 12-bits and chroma subsampling formats ranging from 4:2:0 up to 4:4:4. The IP also features fast and easy SoC integration and is delivered with full user configurable control software.
Guido Meardi, CEO of V-Nova commented “As LCEVC continues its progression in the industry, a holistic suite of hardware IP tools including decoding, encoding, and verification platforms had become essential. Allegro DVT's offerings are perfectly timed to meet this emerging trend, reinforcing the momentum behind LCEVC. Their products will not only fuel LCEVC's adoption but also cement its position as a transformative force that many are already integrating into their plans.”
Nouar Hamze, CEO of Allegro DVT added “With today’s announcement, Allegro DVT has truly become a one-stop-shop for SoC/ASIC designers who need to rapidly add LCEVC encoding/decoding function into their products. Our E301 LCEVC Encoding IP, developed and benchmarked in collaboration with V-Nova, produces the best encoding video quality that fully unlocks the potential of the LCEVC technology. Together with our D301 LCEVC Decoding IP and LCEVC compliance streams, we are enabling an easy and seamless path for SoCs/ASIC companies to integrate and verify the new LCEVC standard into their products, giving them a tremendous competitive advantage.”
MPEG-5 part 2 LCEVC (Low Complexity Enhancement Video Coding) is the latest standard by MPEG and ISO. Instead of replacing existing codecs, LCEVC enhances them, reducing both costs and energy consumption of the transcoding process by up to 70%. Remarkably, it also augments compression efficiency by up to 40%, with benefits that stack upon those of other methods to improve video compression, rather than being an alternative. It specifies an enhancement layer which, when combined with a base video encoded with a separate codec, produces an enhanced video stream. LCEVC also enables unique benefits in applications such as single-stream SDR-HDR backward-compatible delivery and low-latency video delivery.
To find out more about Allegro DVT’s LCEVC products, come and visit Allegro DVT booth 5.A25 at IBC Amsterdam 15-18 September 2023.
About Allegro DVT
Allegro DVT is a world leading provider of digital video technology solutions including compliance streams and video codec semiconductor IPs focused on H.264, HEVC, VP9, AV1, VVC and LCEVC standards.
About V-Nova
V-Nova is committed to unlocking higher quality digital experiences at scale. Its technologies, based on the innovative use of AI and parallel processing improve data, video, imaging, point-cloud compression and have been granted international standard status by MPEG, ISO and SMPTE. V-Nova’s relentless investment in R&D has built a portfolio of over 700 international patents, along with a range of software products and solutions.
For more about V-Nova, please visit: www.v-nova.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831702100/en/
Contact information
Allegro DVT press:
Stéphanie Nastasi – Communication Manager
marcom@allegrodvt.com
V-Nova press:
Jose D. Guariglia – PR Account Manager, Bubble UK and EMEA
jd@bubbleagency.com
Casey Love – PR Account Manager, Bubble USA
caseyl@bubbleagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom